Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: A randomized, double-blind, crossover study

Journal of Clinical Psychiatry

Volumn 68, Issue 8, 2007, Pages 1186-1194

  Harvey, Philip D ^a   Hassman, Howard ^b   Mao, Lian ^c   Gharabawi, Georges M ^c,d   Mahmoud, Ramy A ^c   Engelhart, Luella M ^c,e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CNS Research Institute   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e Department of Medical Affairs and Health Ecomomics Worldwide   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; ATTENTION; BIPOLAR DISORDER; BLURRED VISION; CARPAL TUNNEL SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECLARATIVE MEMORY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSTONIA; FATIGUE; FEMALE; HUMAN; MALE; NAUSEA; NOSE CONGESTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEDATION; SLEEP; SOMNOLENCE; WORKING MEMORY; XEROSTOMIA;

EID: 34548552426     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v68n0804     Document Type: Article

References (48)

1. Casale TB, Blaiss MS, Gelfand E, et al. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003;111:S835-S842
2. Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry 2005;187:229-234
3. Smulevich AB, Khanna S, Eerdekens M, et al. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005;15:75-84
4. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66:111-121
5. Vieta E, Mullen J, Brecher M, et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies. Curr Med Res Opin 2005;21:923-934
6. McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar disorder: a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005;15:573-585
7. Yatham LN, Paulsson B, Mullen J, et al. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004;24:599-606
8. Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2004;6:213-223
9. Rendell JM, Gijsman HJ, Bauer MS, et al. Risperidone alone or in combination for acute mania. Cochrane Database Syst Rev 2006:CD004043
10. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978;133:429-435
11. Montgomery SA, Asberg, MC. A new depression rating scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
12. Sheehan DV, Lecrubier Y, et al. Mini-International Neuropsychiatric Interview (M.I.N.I.). Tampa, Fla: University of South Florida, Institute for Research in Psychiatry, and Paris, France: INSERM-Hôpital de la Salpêtrière; 1994
13. Heykants J, Huang ML, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994; 55(5, suppl):13-17
14. Keck PE Jr, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry 2002;63(suppl 4):3-11
15. Risperdal [package insert]. Titusville, NJ: Janssen LP; 2006. Available at http://www.risperdal.com/active/janus/en_US/assets/common/company/ pi/risperdal.pdf. Accessibility verified February 28, 2007
16. Seroquel [package insert]. Wilmington, Del: AstraZeneca Pharmaceuticals LP; 2005. Available at http://www.astrazeneca-us.com/pi/ seroquel.pdf. Accessibility verified February 28, 2007
17. Gutierrez B, Meletiche D, Rupnow M, et al. Mental health cost comparison among subjects with bipolar disorder, treated with risperidone, olanzapine, or quetiapine in a managed care setting: a propensity-matched cohort study [poster]. Presented at the 6th International Conference on Bipolar Disorder; June 16-18, 2005; Pittsburgh, Pa
18. Mirsky AF, Primac DW, Marsan CA, et al. A comparison of the psychological test performance of patients with focal and nonfocal epilepsy. Exp Neurol 1960;2:75-89
19. Rosvold HE, Mirsky AF, Sarason I, et al. A continuous performance test of brain damage. J Consult Psychol 1956;20:343-350
20. Cornblatt BA, Erlenmeyer-Kimling L. Global attentional deviance as a marker of risk for schizophrenia: specificity and predictive validity. J Abnorm Psychol 1985;94:470
21. Cornblatt BA, Keilp JG. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Res 1994;20:31-46
22. Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L. The continuous performance test, identical pairs version, pt 2: contrasting attentional profiles in schizophrenic and depressed subjects. Psychiatry Res 1989; 29:65-85
23. Posner MI, Inhoff AW, Friedrich FJ, et al. Isolating attentional systems: a cognitive-anatomical analysis. Psychobiology 1987;15:107-121
24. Allen DN, Aldarondo F, Goldstein G, et al. Construct validity of neuropsychological tests in schizophrenia. Assessment 1998;5:365-374
25. Allen DN, Huegel SG, Seaton BE, et al. Confirmatory factor analysis of the WAIS-R in patients with schizophrenia. Schizophr Res 1998; 34:87-94
26. Kaufman AS. Assessing Adolescent and Adult Intelligence. Boston, Mass: Allyn and Bacon, Inc; 1990
27. Kaufman AS, Lichtenberger EO, Mclean JE. Two- and three-factor solutions of the WAIS-III. Assessment 2001;8:267-280
28. Cooper JA, Sagar HJ, Jordan N, et al. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991;114:2095-2122
29. Mesulam MM. Principles of Behavioral Neurology. Philadelphia, Pa: FA Davis; 1985
30. Weintraub S, Mesulam MM. Right cerebral dominance in spatial attention: further evidence based on ipsilateral neglect. Arch Neurol 1987;44:621-625
31. Heun R, Papassotiropoulos A, Jennssen F. The validity of psychometric instruments for detection of dementia in the elderly general population. Int J Geriatr Psychiatry 1998;13:368-380
32. Crossen JR, Wiens AN. Comparison of the Auditory-Verbal Learning Test (AVLT) and California Verbal Learning Test (CVLT) in a sample of normal subjects. J Clin Exp Neuropsychol 1994;16:190-194
33. Wechsler D. The Measurement of Adult Intelligence. 3rd ed. Baltimore, Md: Williams & Wilkins; 1944
34. Smith A. Symbol Digit Modalities Test (SDMT): Manual, Revised. Los Angeles, Calif: Western Psychological Services; 1982
35. Bower EA, Moore JL, Selby KA, et al. The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel. Aviat Space Environ Med 2003;74:145-152
36. Hindmarch I, Shamsi Z, Stanley N, et al. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol 1999;48:200-201
37. Judd LL. The effect of antipsychotic drugs on driving and driving-related psychomotor function. Accid Anal Prev 1985;17:319-322
38. Kamei H, Noda Y, Ishikawa K, et al. Comparative study of acute effects of single doses of fexofenadine, olopatadine, chlorpheniramine, and placebo on psychomotor function in healthy volunteers. Hum Psychopharmacol 2003;18:611-618
39. Lee KA, Hicks G, Nino-Jurcia G. Validity and reliability of a scale to assess fatigue. Psychiatry Res 1991;36:291-298
40. Neuchterlein KH, Barch DM, Gold JM, et al. Identification of separable cognitive factors in schizophrenia. Schizophr Res 2004;72:29-39
41. Bryant J, Clegg A, Nicholson T, et al. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol Assess 2001;5:1-137
42. Caro J, Ward A, Ishak K, et al. To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers? BMC Neurol 2001;2:6
43. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-592
44. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159:1018-1028
45. Sajatovic M, Blow FC, Kales HC, et al. Age comparison of treatment adherence with antipsychotic medications among individuals with bipolar disorder. Int J Geriatr Psychiatry 2007;Feb 23 [epub ahead of print]
46. Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006;8: 232-241
47. Colom F, Vieta E, Martinez-Aran A, et al. Clinical factors associated with treatment noncompliance in euthymic bipolar patients. J Clin Psychiatry 2000;61:549-555
48. Keck PE Jr, McElroy SL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998;155:646-652